William R. Gwin III, MD, discusses potential areas of investigation with the combination of alpha-tocopheryloxyacetic acid (alpha-TEA) and trastuzumab (Herceptin) in breast cancer.
William R. Gwin III, MD
Advertisement
Articles by William R. Gwin III, MD
William R. Gwin III, MD, discusses the mechanism of action of alpha-tocopheryloxyacetic acid in HER2-positive metastatic breast cancer.
William R. Gwin III, MD, discusses the safety profile of alpha-tocopheryloxyacetic acid in combination with trastuzumab in recurrent HER2-positive metastatic breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
4
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
5